BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27160232)

  • 1. Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study.
    Wallace SK; Lin JF; Cliby WA; Leiserowitz GS; Tergas AI; Bristow RE
    J Natl Compr Canc Netw; 2016 May; 14(5):539-50. PubMed ID: 27160232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
    Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
    JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
    Phippen NT; Barnett JC; Lowery WJ; Miller CR; Leath CA
    Gynecol Oncol; 2013 Oct; 131(1):158-62. PubMed ID: 23872110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
    Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
    Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
    Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.
    Dinkelspiel HE; Tergas AI; Zimmerman LA; Burke WM; Hou JY; Chen L; Hillyer G; Neugut AI; Hershman DL; Wright JD
    Gynecol Oncol; 2015 May; 137(2):203-9. PubMed ID: 25703674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.
    Hodeib M; Chang J; Liu F; Ziogas A; Dilley S; Randall LM; Anton-Culver H; Bristow RE
    Gynecol Oncol; 2015 Jul; 138(1):121-7. PubMed ID: 25913132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
    Nasioudis D; Mastroyannis SA; Albright BB; Haggerty AF; Ko EM; Latif NA
    Gynecol Oncol; 2018 Jul; 150(1):14-18. PubMed ID: 29751993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
    Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
    J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
    Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in epithelial ovarian cancer: A population-based study.
    Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
    PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
    Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-Based Analysis of Patient Age and Other Disparities in the Treatment of Ovarian Cancer in Central Appalachia and Kentucky.
    Ore RM; Chen Q; DeSimone CP; Miller RW; Baldwin LA; van Nagell JR; Huang B; Tucker TC; Johnson MS; Fredericks TI; Ueland FR
    South Med J; 2018 Jun; 111(6):333-341. PubMed ID: 29863220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.